Research library

Epithalon Research Overview: Telomerase-Related Findings, Pineal Peptide Origins and Evidence Quality

Compiled by:: Peptide Pilots Scientific Content Team
Reviewed by:: Peptide Pilots Quality & Compliance review
Last revised:: 3 September 2026

What is the evidentiary basis for Epithalon's reputation as a longevity-related peptide, and how independent is that literature?

Epithalon (Ala-Glu-Asp-Gly, AEDG) is a synthetic tetrapeptide designed as the presumed active fragment of epithalamin, a polypeptide pineal-gland extract studied since the 1980s by Vladimir Khavinson's laboratory in Saint Petersburg. Published work from that group and collaborators reports telomerase activation and telomere-length effects in cultured human cells, extended lifespan and reduced spontaneous tumour incidence in rodent studies, and normalisation of melatonin and other circadian markers in small human studies of older adults. Nearly all primary studies originate from a single research group and affiliated institutes, independent replication is limited, and no regulatory-grade human efficacy trial exists.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is Epithalon?

Epithalamin is a polypeptide extract prepared from bovine pineal gland tissue, studied in the Russian gerontological literature since the 1980s as part of a broader 'bioregulator peptide' research programme.

Epithalon is a four-amino-acid synthetic peptide (Ala-Glu-Asp-Gly) proposed as a simplified, chemically defined analogue capturing part of epithalamin's reported biological activity, allowing it to be manufactured and dosed with more consistency than the crude extract.

Epithalon names and identifiers

Also referred to as: Epitalon; Epithalamin analogue; AEDG peptide; Ala-Glu-Asp-Gly

Sequence	Ala-Glu-Asp-Gly (AEDG)
Molecular formula	C13H19N3O9
Average molecular weight	≈378.3 g/mol
CAS number	307297-39-8
Originating institute	Saint Petersburg Institute of Bioregulation and Gerontology
Regulatory status	Not approved by the FDA or EMA; studied and marketed within Russia under gerontological research programmes

Epithalon research background

Khavinson and colleagues developed a series of short peptide 'bioregulators' from bovine tissue extracts, proposing tissue-specific short peptides that modulate gene expression in an epigenetic-like manner; epithalamin was the pineal-derived member of this series.

Epithalon was synthesised as a defined tetrapeptide intended to reproduce epithalamin's reported effects, including reported normalisation of melatonin secretion, antioxidant enzyme activity and circadian rhythm markers in ageing animals.

From the late 1990s the same laboratory published reports of telomerase activation and telomere elongation with Epithalon exposure in cultured human somatic cells, positioning the peptide within the broader telomere-ageing hypothesis literature.

Proposed Epithalon mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

Epithalon in-vitro and cell-based evidence

Reported to activate telomerase and increase telomere length in cultured human fibroblasts and other somatic cell lines in studies from the originating laboratory, using telomerase repeat-amplification protocol (TRAP) assays.
Proposed to influence gene expression at the chromatin level, consistent with the broader 'peptide bioregulator' framework in which short peptides are hypothesised to interact with DNA or histones rather than a defined cell-surface receptor.
No conventional high-affinity receptor for Epithalon has been identified in the independent pharmacological literature.

Epithalon animal-model evidence

Rodent studies from the same research group report modestly increased mean and maximum lifespan and reduced spontaneous tumour incidence with long-term Epithalon or epithalamin administration in several strains, including cancer-prone lines.
Studies report restoration of age-related decline in melatonin rhythm and some immune and antioxidant markers in aged rodents.

Published Epithalon human-study evidence

Small studies from the originating institute report normalisation of melatonin excretion rhythms and some haematological and antioxidant markers in elderly cohorts given epithalamin or Epithalon over short courses.
No randomised, placebo-controlled trial meeting current reporting standards (e.g. CONSORT), and no trial outside the originating research network, has been published in the indexed literature reviewed for this summary.

Published Epithalon studies

Selected published studies involving Epithalon
Study	Model / type	Research question	Main observation	Citation
Khavinson et al., telomerase activation	Cultured human somatic cells (TRAP assay)	Does Epithalon activate telomerase and affect telomere length in vitro?	Reported telomerase activation and telomere elongation in treated cultures relative to untreated controls.	Bulletin of Experimental Biology and Medicine, 2003
Anisimov et al., rodent lifespan and carcinogenesis	Rodent, long-term epithalamin/Epithalon administration	Does pineal-peptide administration affect lifespan and spontaneous tumour incidence?	Reported increased mean lifespan and reduced spontaneous tumour incidence in several rodent strains.	International Journal of Cancer, 2003
Khavinson et al., elderly cohort melatonin study	Human, small cohort of elderly participants	Does epithalamin/Epithalon normalise melatonin rhythm in older adults?	Reported partial normalisation of nocturnal melatonin excretion in treated participants relative to baseline.	Neuroendocrinology Letters, Special Issue, 2001

Limitations of the Epithalon evidence

The overwhelming majority of primary studies, including all major telomerase and lifespan findings, originate from a single laboratory group and its direct collaborators, with very limited independent replication in the international literature.
Reported human studies are small, often lack adequate blinding or placebo control, and are published mainly in Russian-language or lower-visibility journals, which restricts independent verification of methodology.
No trial meeting current international randomised-controlled-trial reporting standards has been published, and no regulatory agency has evaluated Epithalon for a human indication.
The proposed mechanism (direct peptide interaction with chromatin or gene regulatory elements) is not supported by a defined receptor or established pharmacological pathway recognised outside this research programme.
Telomerase activation itself is a biologically double-edged finding, since telomerase reactivation is also a feature of many cancers, and this tension is not fully addressed in the primary literature.

Epithalon laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

Appearance	White lyophilised powder
Solubility	Water-soluble; a small, highly polar tetrapeptide
Lyophilised storage	Commonly stored at −20 °C, desiccated and protected from light
Reconstituted handling	Kept refrigerated and used within a short window in research protocols
Analytical testing	RP-HPLC purity and MS identity are the standard reagent-grade checks reported by suppliers
Stability considerations	As a short, unmodified peptide it is generally stable when kept cold and dry, though batch purity varies across suppliers

Frequently asked Epithalon research questions

Is Epithalon the same as epithalamin?

No. Epithalamin is a crude bovine pineal polypeptide extract; Epithalon is a defined four-amino-acid synthetic peptide (Ala-Glu-Asp-Gly) developed as a proposed active-fragment analogue of it.

Has Epithalon been shown to extend human lifespan?

No. Lifespan and tumour-incidence findings come from rodent studies. Human studies are small, short-duration and focused on markers such as melatonin rhythm, not survival outcomes.

Why is the telomerase finding significant, and why is it also a caution?

Telomerase activity is linked to cellular replicative capacity and is of interest in ageing research, but telomerase reactivation is also a hallmark of many cancers, so activation findings require careful, independent safety evaluation that has not yet been published.

Is this peptide approved for medical use anywhere?

No major regulatory agency (FDA, EMA) has approved Epithalon for any indication; it is studied and used within a specific Russian gerontological research and clinical programme.

Epithalon primary references

Khavinson VK, Bondarev IE, Butyugov AA (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. https://doi.org/10.1023/A:1024680330393
Anisimov VN, Khavinson VK, Provinciali M, et al. (2003). Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. https://doi.org/10.1002/ijc.11292
Khavinson VK (2001). Peptides and ageing. Neuroendocrinology Letters, Special Issue. https://pubmed.ncbi.nlm.nih.gov/12374939/

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published 25 August 2026; last revised 3 September 2026. Pages are revised when the cited literature changes materially.

Catalogue reference

Peptide Pilots supplies Epithalon as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.

View Epithalon catalogue entry